Literature DB >> 16015014

Natural history of progressive supranuclear palsy: a clinicopathologic study from a population of brain donors.

Spiridon Papapetropoulos1, Jocely Gonzalez, Deborah C Mash.   

Abstract

Progressive supranuclear palsy (PSP) is the second most common parkinsonian syndrome, characterized by a 'diverse' clinical phenotype. Although several different diagnostic guidelines have been proposed, the early and accurate diagnosis of PSP remains problematic and neuropathology is still considered the 'gold standard'. In order to contribute to the better clinical characterization of PSP, we conducted a postmortem study in a cohort of 22 consecutive PSP brain donors and compared our results with those of previously published reports. Our results further demonstrate and expand the varied clinical picture of PSP. Furthermore, we report associations between older age at onset, early dementia, early falls and smoking with shorter PSP duration. (c) 2005 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2005        PMID: 16015014     DOI: 10.1159/000086754

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  13 in total

1.  "Rapidly" Progressive Supranuclear Palsy.

Authors:  Melissa J Armstrong; Rudy J Castellani; Stephen G Reich
Journal:  Mov Disord Clin Pract       Date:  2014-04-10

2.  Current and future treatments in progressive supranuclear palsy.

Authors:  Irene van Balken; Irene Litvan
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.598

3.  Spatial patterns of the tau pathology in progressive supranuclear palsy.

Authors:  Richard A Armstrong; Nigel J Cairns
Journal:  Neurol Sci       Date:  2012-03-13       Impact factor: 3.307

Review 4.  Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy.

Authors:  Maria Stamelou; Jakob Schöpe; Stefan Wagenpfeil; Teodoro Del Ser; Jee Bang; Iryna Y Lobach; Phi Luong; Gesine Respondek; Wolfgang H Oertel; AdamL Boxer; Günter U Höglinger
Journal:  Mov Disord       Date:  2016-03-07       Impact factor: 10.338

5.  Progressive supranuclear palsy (PSP): a quantitative study of the pathological changes in cortical and subcortical regions of eight cases.

Authors:  R A Armstrong; P L Lantos; N J Cairns
Journal:  J Neural Transm (Vienna)       Date:  2007-08-07       Impact factor: 3.575

Review 6.  [Treatment for dementia in parkinsonian syndromes. Efficacy of cholinesterase inhibitors].

Authors:  I Liepelt; W Maetzler; H-P Blaicher; T Gasser; D Berg
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

7.  Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study.

Authors:  Milica Jecmenica-Lukic; Igor N Petrovic; Tatjana Pekmezovic; Vladimir S Kostic
Journal:  J Neurol       Date:  2014-06-03       Impact factor: 4.849

8.  Impact of Aspiration Pneumonia on the Clinical Course of Progressive Supranuclear Palsy: A Retrospective Cohort Study.

Authors:  Satoshi Tomita; Tomoko Oeda; Atsushi Umemura; Masayuki Kohsaka; Kwiyoung Park; Kenji Yamamoto; Hiroshi Sugiyama; Chiaki Mori; Kimiko Inoue; Harutoshi Fujimura; Hideyuki Sawada
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

9.  Clinical features and disability milestones in multiple system atrophy and progressive supranuclear palsy.

Authors:  Sang-Wook Lee; Seong-Beom Koh
Journal:  J Mov Disord       Date:  2012-10-30

10.  Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database.

Authors:  Emma Viscidi; Irene Litvan; Tien Dam; Maneesh Juneja; Li Li; Henry Krzywy; Susan Eaton; Susan Hall; Joseph Kupferman; Günter U Höglinger
Journal:  Front Neurol       Date:  2021-06-17       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.